These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 8831191)
21. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review]. Amitani R; Kuze F Kekkaku; 1994 Nov; 69(11):711-7. PubMed ID: 7837725 [TBL] [Abstract][Full Text] [Related]
22. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648. Tomioka H Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623 [TBL] [Abstract][Full Text] [Related]
23. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare]. Truffot-Pernot C; Giroir AM; Maury L; Grosset J Rev Mal Respir; 1988; 5(4):401-6. PubMed ID: 2845531 [TBL] [Abstract][Full Text] [Related]
24. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658 [TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae. Dhople AM Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513 [TBL] [Abstract][Full Text] [Related]
26. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Heifets LB; Lindholm-Levy PJ; Iseman MD Am Rev Respir Dis; 1988 Mar; 137(3):719-21. PubMed ID: 2830815 [TBL] [Abstract][Full Text] [Related]
27. Bactericidal action at low doses of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on Mycobacterium leprae inoculated into footpads of nude mice. Gidoh M; Tsutsumi S; Yamane T; Yamashita K; Hosoe K; Hidaka T Lepr Rev; 1992 Dec; 63(4):319-28. PubMed ID: 1479871 [TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Tomioka H; Saito H; Fujii K; Sato K; Hidaka T Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020 [TBL] [Abstract][Full Text] [Related]
29. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Heifets LB; Lindholm-Levy PJ; Flory MA Am Rev Respir Dis; 1990 Mar; 141(3):626-30. PubMed ID: 2155555 [TBL] [Abstract][Full Text] [Related]
30. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351 [TBL] [Abstract][Full Text] [Related]
31. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Moghazeh SL; Pan X; Arain T; Stover CK; Musser JM; Kreiswirth BN Antimicrob Agents Chemother; 1996 Nov; 40(11):2655-7. PubMed ID: 8913484 [TBL] [Abstract][Full Text] [Related]
32. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections]. Kawahara S; Nagare H Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700 [TBL] [Abstract][Full Text] [Related]
33. [The studies on the molecular mechanism of rifampin-resistant Mycobacterium tuberculosis]. Zhuang Y; He X; Zhang X Zhonghua Jie He He Hu Xi Za Zhi; 2000 Dec; 23(12):711-4. PubMed ID: 11778472 [TBL] [Abstract][Full Text] [Related]
34. [Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains]. Gao L; Xiao HP; Hu ZY; Cui ZL; Lu JM; Shen XN Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):333-5. PubMed ID: 22883990 [TBL] [Abstract][Full Text] [Related]
35. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Uzun M; Erturan Z; Anğ O Int J Tuberc Lung Dis; 2002 Feb; 6(2):164-5. PubMed ID: 11931417 [TBL] [Abstract][Full Text] [Related]
36. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans. Dhople AM Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650 [TBL] [Abstract][Full Text] [Related]
37. [A new anti-mycobacterial agent, rifabutin]. Kurashima A; Mori T; Tomono Y; Abe S; Nagaoka M; Abe M Kekkaku; 2010 Oct; 85(10):743-56. PubMed ID: 21061564 [TBL] [Abstract][Full Text] [Related]
38. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. Rastogi N; Goh KS; Berchel M; Bryskier A J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253 [TBL] [Abstract][Full Text] [Related]